Table 1.

Data of the Likert scale mean values of the selected statements to rate the clinical importance (round 1) and the need for identification (round 2) of anthracycline- and patient-related risk factors for cardiac toxicity in early-stage breast cancer

Early-stage breast cancer	Importance (round 1)		Need (round 2)		Statistical differences (p value)
	Participants (n)	Mean Likert score	Participants (n)	Mean Likert score	Round 1 vs. round 2	Job positions	Number of beds
Cardiac risk related to treatment
Cumulative dose of anthracyclines ≥450 mg/m2	98	6.7	100	6.7	0.513	0.9513	0.8138
Combination of drugs	99	6.2	100	6.4	0.0845	0.4645	0.0067*
Thoracic radiation therapy	100	5.5	100	5.8	0.0188*	0.6155	0.6090
Anthracycline dose per cycle	100	4.9	100	5.5	0.0054*	0.1874	0.0377*
Cardiac risk related to patient
Preexisting cardiac disease	98	6.4	100	6.7	0.0009*	0.1630	0.3307
Hypertension	100	5.4	100	5.8	0.0007*	0.050	0.6420
Age (>65 y.o.)	100	5.2	100	5.6	0.0016*	0.0051*	0.1844
Obesity	100	5.2	100	5.5	0.0164*	0.0060*	0.5195
Diabetes	100	5.1	100	5.6	0.0029*	0.0024*	0.9107
Smoking	100	4.8	100	5.3	0.0152*	0.0129*	0.7588
Hypercholesterolemia	100	4.4	100	5.0	0.0007*	0.0104*	0.6088
Physical inactivity	100	4.3	100	4.9	0.0029*	0.0024*	0.9107

Numbers in bold represent the highest degree of agreement according to the Likert used Scale (1–7)

Likert scale ranged from 1—not important/no need at all to 7—highly important absolutely needed. Comparisons between round 1 & 2 and among groups (job positions and hospital size) were also analyzed

* p < 0.05 was considered statistically significant